Phase II Trial of Nelfinavir With Concurrent Chemoradiotherapy in Squamous Cell Carcinoma of the Head and Neck

NCT02207439 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

18

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma

Interventions

DRUG: Nelfinavir (Viracept®) 1250 mg
OTHER: Chemoradiation

Sponsor

Abramson Cancer Center at Penn Medicine